您现在的位置:网站首页>通知公告

通知公告

【医学部学术讲座】——The role of academic institutes in R&D of TCM outside Chinese Mainland

文章来源: 作者: 发布时间:2017年03月15日 点击数: 字体:

Professor Kelvin CHAN (陈金泉)  was initially trained in Pharmaceutical Industry; further developed in clinical pharmacology, drug metabolism and pharmacokinetics at medical schools in University of Birmingham (PhD & DSc) and University of Liverpool (Post-doctor fellow), United Kingdom, Finders Medical School in Adelaide, Australia and Karolinska Institute in Sweden; started interests in R&D of traditional Chinese medicine since early1990s at the Chinese University of Hong Kong. He has taught medicinal pharmacology in universities in the UK, Hong Kong, UAE and Australia. Currently he is Visiting Professor of Natural Products and TCM Research at Liverpool John Moores University, UK and Adjunct Professor in TCM Research at University of Technology Sydney and Western University in Australia.  He has published 3 specialist books on Chinese medicine, over 600 hundred publications including keynotes/conference presentation, drug monographs, and peer-reviewed papers (260) in conventional medicine and TCM. My present research directions and interests focus towards the R&D of Chinese medicines and natural products using technology developed from systems biology, as well as Evidence-Based Medicine in TCM practice. He has  supervised and co-supervised 33 postgraduates (25 PhD and 8 MSc/MPhil). He is presently member of the following boards/committee: International Advisory Board and Scientific Committee of the Hong Kong Chinese Materia Medica Standards, Department of Health, Hong Kong (Feb 2002 to present); WHO Temporary Advisor on Training Course of Quality Control of Herbal Medicine (2013 to present); Board of Directors of the Good Practice in TCM Research Association (2012 to 2016); Australia Observer at the TCM Working Group of the European Directorate for Quality of Medicine & Healthcare, in Strasbourg on monographs for the Chinese materia medica for the European Pharmacopoeia (March 2010 to 2014);  Advisory Board of the Consortium for Globalisation of Chinese Medicine (2010 to Present).

【打印文章】 【添加收藏】